# Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma

> **NCT04817254** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 47 (actual)

## Conditions studied

- Glioblastoma
- Gliosarcoma
- Malignant Glioma

## Interventions

- **DRUG:** TMZ
- **DRUG:** ipilimumab 3mg/kg
- **DRUG:** Nivolumab
- **DRUG:** ipilimumab 1mg/kg

## Key facts

- **NCT ID:** NCT04817254
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-12-08
- **Primary completion:** 2026-03-20
- **Final completion:** 2026-03-20
- **Target enrollment:** 47 (ACTUAL)
- **Last updated:** 2026-04-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04817254

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04817254, "Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or Gliosarcoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04817254. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*